**Clinical Trial Phases**

- **Phase I**: The goal is to test the safety of the drug, finding the appropriate dose that produces the fewest side effects.
- **Phase II**: Further assesses the safety of the drug and the effectiveness of the treatment.
- **Phase III**: Compares the efficacy of the new treatment to the standard-of-care treatment.
- **Phase IV**: Study that looks at drugs that have already been approved to get additional safety information and to learn more about long-term benefits and side effects.

**Resources for CLL Clinical Trial Information**

- Clinicaltrials.gov
- CLL Society: cllsociety.org
- The Leukemia & Lymphoma Society: llsls.org
- Lymphoma Research Foundation: lymphoma.org
- National Organization for Rare Disorders (NORD): raredisease.org

**Common Clinical Trial Terminology**

- **Health Insurance Portability and Accountability Act (HIPAA)**: A set of national rules that help protect the privacy of a patient’s personal medical information, provide patients with access to their medical records, and help people get health insurance for themselves and their family members.
- **Informed Consent**: Provides a thorough explanation of the purpose of the research, including the role of the patient and how the trial will work.
- **Institutional Review Board (IRB)**: Committees that ensure that the risks of trial participation are reduced and outweighed by potential benefits in order to protect the rights and safety of research participants. Most clinical trials, but not all, in the United States are approved and monitored by an IRB both before the research starts and as it proceeds.
- **Placebo**: An inactive drug or treatment with no therapeutic benefit.
- **Protocol**: The written description of a clinical study that includes the objectives, design, and methods. The protocol may also include scientific background and statistical information that pertains to the study.
- **Standard of Care**: An established guideline that is consensus among experts as the most appropriate and/or effective treatment for a specific type and stage of cancer.

**MORE TOOLS FOR EMPOWERMENT**

- Digitally Empowered™
- PEN-Powered Activity Guide
- Empowered Blog
- Empowered! Podcast

CLL Clinical Trials 201 is brought to you by the Patient Empowerment Network. Funding is provided by an unrestricted educational grant from Phamaracylics, an AbbVie Company, and Janssen Biotech, Inc.

question@powerfulpatients.org

@power4patients

PowerfulPatients.org

© 2022 Patient Empowerment Network, a 501(c)(3) Public Charity

www.powerfulpatients.org